Key result
PVI plus additional ablation shows no benefit over PVI alone and links to more AF admissions.
Why the study?
The registry was designed to investigate contemporary ablation approaches and outcomes for patients with paroxysmal AF and non-paroxysmal AF in Europe.
Does PVI plus additional ablation reduce arrhythmia recurrence compared to PVI alone in patients with atrial fibrillation?
Cohort (n=3,446)
Yes
Does PVI plus additional ablation reduce arrhythmia recurrence compared to PVI alone in patients with atrial fibrillation?
In patients with paroxysmal and non-paroxysmal AF, additional ablation beyond PVI (PVIplus) did not improve 1-year arrhythmia-free survival compared to PVI alone, but was associated with higher hospital readmission rates.
Additional ablation beyond PVI should not yet change practice; leaves open efficacy in targeted subgroups for randomized trials.
AIMS: The ESC EORP EHRA Atrial Fibrillation (AF) Ablation Long-Term registry was designed to assess management and outcomes of AF catheter ablation procedures in Europe. To investigate the current ablation approaches and their outcomes for patients with paroxymal AF (PAF) and non-PAF in Europe. METHODS AND RESULTS: Data from index ablations were collected in 27 European countries at 104 centres in a prospective fashion. Pre-procedural, procedural, and 1-year follow-up data were captured on a web-based electronic case record form. Data on the ablation procedure were available for 3446 patients. Of these, 2513 patients and 933 patients underwent pulmonary vein isolation (PVI) or PVI plus (PVIplus) additional ablation, respectively. The ablation strategy was limited to PVI in 81% and 56% of patients in the PAF and non-PAF group, respectively (P < 0.001). In the non-PAF group, left atrial linear ablation and ablation of complex fragmented atrial electrograms were more commonly performed. Arrhythmias recurrence after PVI was 29% and 39% in the PAF and non-PAF group, respectively (P < 0.001) and 42% after PVIplus in both groups. Atrial fibrillation related hospital admissions were more common in the PVIplus group (20% vs. 14%). A very low procedural complication rate was observed. No relevant differences were observed with regard to repeat ablation (PVI 9% and PVIplus 11%). CONCLUSION: In patients with PAF and non-PAF, the ablation strategies of PVI and PVIplus led to similar arrhythmia-free survival rates after 1 year. A considerable hospital readmission rate was noted.
No takes yet. Share an insight, caveat, or question.
Schmidt et al. (2019) conducted a cohort in Atrial Fibrillation (n=3,446). Pulmonary vein isolation plus additional ablation (PVIplus) vs. Pulmonary vein isolation (PVI) alone was evaluated on Arrhythmias recurrence. Pulmonary vein isolation plus additional ablation led to similar 1-year arrhythmia-free survival compared to PVI alone, but was associated with higher AF-related hospital admissions (20% vs 14%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: